NasdaqGS - Delayed Quote • USD
Generation Bio Co. (GBIO)
At close: 4:00 PM EDT
After hours: 5:35 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -0.41 | -0.38 | -1.49 | -1.3 |
| Low Estimate | -0.57 | -0.52 | -2.04 | -1.96 |
| High Estimate | -0.27 | -0.24 | -1.06 | -0.52 |
| Year Ago EPS | -0.53 | -0.47 | -1.96 | -1.49 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 1.92M | 1.82M | 7.84M | 6.66M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 3M | 3M | 13M | 12.32M |
| Year Ago Sales | 7.92M | 880k | 5.9M | 7.84M |
| Sales Growth (year/est) | -75.80% | 106.80% | 32.80% | -15.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.46 | -0.5 | -0.5 | -0.45 |
| EPS Actual | -0.53 | -0.47 | -0.43 | -0.53 |
| Difference | -0.07 | 0.03 | 0.07 | -0.08 |
| Surprise % | -15.20% | 6.00% | 14.00% | -17.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.41 | -0.38 | -1.49 | -1.3 |
| 7 Days Ago | -0.41 | -0.38 | -1.49 | -1.3 |
| 30 Days Ago | -0.43 | -0.39 | -1.54 | -1.32 |
| 60 Days Ago | -0.43 | -0.43 | -1.68 | -1.35 |
| 90 Days Ago | -0.43 | -0.43 | -1.68 | -1.35 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GBIO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 22.60% | -- | -- | 1.50% |
| Next Qtr. | 19.10% | -- | -- | 11.40% |
| Current Year | 24.00% | -- | -- | 5.20% |
| Next Year | 12.80% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/10/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 3/7/2024 |
| Maintains | Needham: Buy to Buy | 3/7/2024 |
| Maintains | Wedbush: Outperform to Outperform | 11/10/2023 |
| Downgrade | JMP Securities: Market Outperform to Market Perform | 10/23/2023 |
| Downgrade | TD Cowen: Outperform to Market Perform | 10/19/2023 |
Related Tickers
PMVP PMV Pharmaceuticals, Inc.
1.6900
-6.37%
IPSC Century Therapeutics, Inc.
2.9600
-5.43%
ALXO ALX Oncology Holdings Inc.
16.22
+4.65%
BCAB BioAtla, Inc.
2.3500
+4.91%
ALGS Aligos Therapeutics, Inc.
0.8290
+0.66%
CGEM Cullinan Therapeutics, Inc.
18.89
+13.32%
FDMT 4D Molecular Therapeutics, Inc.
24.25
-2.26%
GLTO Galecto, Inc.
0.6710
-4.22%
ANNX Annexon, Inc.
4.4500
+0.23%
ANAB AnaptysBio, Inc.
19.27
+0.47%